Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far Upinder KaurBhairav Kumar PathakSankha Shubhra Chakrabarti Review Article 09 March 2024 Pages: 223 - 250
An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients David P. WallingSunita N. ShindeCeline M. Laffont Original Research Article Open access 22 February 2024 Pages: 251 - 260
Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan Teppei HaginoRisa HamadaNaoko Kanda Original Research Article 06 March 2024 Pages: 261 - 269
Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE) Xi TanVictoria DivinoAaron A. King Original Research Article Open access 20 March 2024 Pages: 271 - 284
Experience of Tofacitinib Use in Pregnancy in Patients with Ulcerative Colitis María ChaparroDaniel CeballosJavier P. Gisbert Research Letter Open access 19 March 2024 Pages: 285 - 288
Tolvaptan Treatment and Long-Term Impact on Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients: A Pilot Study Gianni CarraroValentina Di VicoLorenzo A. Calò Research Letter 02 March 2024 Pages: 289 - 291